Hansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialise innovative, lifesaving and life-altering treatments for patients with rare immunological conditions.
The company has a rich and expanding research and development program based on its proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in autoimmune diseases, gene therapy and transplantation.
The company’s portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitised patients and HNSA-5487, a next-generation IgG cleaving molecule with redosing potential.
Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the US.Th e company is listed on Nasdaq Stockholm under the ticker HNSA.
